{"prompt": "['completion of steroid taper.', 'methylprednisolone or IV equivalent) and prompt', 'Patients with endocrinopathies who may', 'initiation of treatment with relevant hormone', 'require prolonged or continued steroid', 'replacement (e.g., hydrocortisone, sex hormones).', 'replacement (e.g., adrenal insufficiency)', 'Isolated hypothyroidism may be treated with', 'can be retreated with study drug/study', 'replacement therapy, without study drug/study regimen', 'regimen on the following conditions:', 'interruption, and without corticosteroids.', 'Isolated Type 1 diabetes mellitus (DM) may be treated', '1.', 'The event stabilizes and is', 'with appropriate diabetic therapy, without study', 'controlled.', 'drug/study regimen interruption, and without', '2.', 'The patient is clinically stable as', 'corticosteroids.', 'per investigator or treating', 'Once patients on steroids are improving, gradually taper', \"physician's clinical judgement.\", 'immunosuppressive steroids (as appropriate and with', '3.', 'Doses of prednisone are', 'guidance of endocrinologist) over >28 days and', '10 mg/day or equivalent.', 'consider prophylactic antibiotics, antifungals, and anti-', 'PJP treatment (refer to current NCCN guidelines for', 'treatment of cancer-related infections [Category 2B', 'recommendation]).', 'For patients with normal endocrine workup (laboratory', 'assessment or MRI scans), repeat laboratory', 'assessments/MRI as clinically indicated.', 'Grade 3 or 4', 'For Grade 3 or 4 endocrinopathy other', 'Consult endocrinologist to guide evaluation of endocrine', 'than hypothyroidism and Type', '1', 'function and, as indicated by suspected endocrinopathy', 'diabetes mellitus, hold study drug/study', 'and as clinically indicated, consider pituitary scan.', 'regimen dose until endocrinopathy', 'Hospitalization recommended.', 'symptom(s) are controlled.', 'For all patients with abnormal endocrine work up, except', 'Study drug/study regimen can be', 'those with isolated hypothyroidism or Type 1 DM, and as', 'resumed once event stabilizes and after', 'guided by an endocrinologist, promptly initiate empiric IV', 'completion of steroid taper.', 'methylprednisolone 1 to 2 mg/kg/day or equivalent, as', 'Patients with endocrinopathies who may', 'well as relevant hormone replacement (e.g.,', 'require prolonged or continued steroid', 'hydrocortisone, sex hormones).', 'replacement (e.g., adrenal insufficiency)', 'For adrenal crisis, severe dehydration, hypotension, or', 'can be retreated with study drug/study', 'shock, immediately initiate IV corticosteroids with', 'regimen on the following conditions:', 'mineralocorticoid activity.', '1.', 'The event stabilizes and is', 'Isolated hypothyroidism may be treated with replacement', 'controlled.', 'therapy, without study drug/study regimen interruption,', '2.', 'The patient is clinically stable as', 'and without corticosteroids.', 'per investigator or treating', 'Isolated Type 1 diabetes mellitus may be treated with', \"physician's clinical judgement.\", 'appropriate diabetic therapy, without study drug/study', '3.', 'Doses of prednisone are', 'regimen interruption, and without corticosteroids.', '<10 mg/day or equivalent.', 'Once patients on steroids are improving, gradually taper', 'immunosuppressive steroids (as appropriate and with', 'guidance of endocrinologist) over >28 days and consider', 'prophylactic antibiotics, antifungals, and anti-PJP', 'treatment (refer to current NCCN guidelines for treatment', 'of cancer-related infections [Category 2B', 'recommendation]).', 'asco Educational Book 2015 \"Managing Immune Checkpoint Blocking Antibody Side Effects\" by Michael Postow MD.', 'Neurotoxicity imAEs', 'Neurotoxicity', 'Management', 'Follow-up', 'Grade 1', 'No dose modifications.', 'Patients should be evaluated to rule out any alternative', 'etiology (e.g., disease progression, infections, metabolic', 'syndromes, or medications).', 'Monitor patient for general symptoms (headache, nausea,', 'vertigo, behavior change, or weakness).', 'Consider appropriate diagnostic testing (e.g.,', 'electromyogram and nerve conduction investigations).', 'Perform symptomatic treatment with neurological consult', 'as appropriate.', 'Grade 2', 'For acute motor neuropathies or', 'Consider, as necessary, discussing with the study', 'neurotoxicity, hold study drug/study', 'physician.', 'regimen dose until resolution to Grade', 'Obtain neurology consult.', '<1.', 'Sensory neuropathy/neuropathic pain may be managed', 'For sensory neuropathy/neuropathic', 'by appropriate medications (e.g., gabapentin or', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 32 de 123']['pain, consider holding study drug/study', 'duloxetine).', 'regimen dose until resolution to Grade', 'Promptly start systemic steroids prednisone 1 to 2', '1.', 'mg/kg/day PO or IV equivalent.', 'If toxicity worsens, then treat as Grade', 'If no improvement within 3 to 5 days despite 1 to 2', '3 or 4.', 'mg/kg/day prednisone PO or IV equivalent, consider', 'Study drug/study regimen can be', 'additional workup and promptly treat with additional', 'resumed once event improves to Grade', 'immunosuppressive therapy (e.g., IV immunoglobulin).', '1 and after completion of steroid taper.', 'Grade 3 or 4', 'For Grade 3:', 'Consider, as necessary, discussing with study physician.', 'Hold study drug/study regimen dose', 'Obtain neurology consult.', 'until resolution to Grade 1.', 'Consider hospitalization.', 'Permanently discontinue', 'study Promptly initiate empiric IV methylprednisolone 1 to 2', 'drug/study regimen if Grade 3 imAE', 'mg/kg/day or equivalent.', 'does not resolve to Grade 1 within 30', 'If no improvement within 3 to 5 days despite IV', 'days.', 'corticosteroids, consider additional workup and promptly', 'treat with additional immunosuppressants (e.g., IV', 'For Grade 4:', 'immunoglobulin).', 'Permanently', 'discontinue', 'study', 'Once stable, gradually taper steroids over >28 days.', 'drug/study regimen.', 'Peripheral neuromotor', 'syndromes', 'Management', 'Follow-up', '(such as Guillain-Barre and', 'myasthenia gravis)', 'Grade 1 (Asymptomatic)', 'No dose modifications.', 'Consider, as necessary, discussing with the study', 'physician.', 'Care should be taken to monitor patients for sentinel', 'symptoms of a potential decompensation', 'Obtain a neurology consult.', 'Grade 2 (Moderate', 'Hold study drug/study regimen dose', 'Consider, as necessary, discussing with the study', 'symptoms; limiting', 'until resolution to Grade 1.', 'physician.', 'instrumental activities of', 'Permanently discontinue study', 'Care should be taken to monitor patients for sentinel', 'daily living [ADLs])', 'drug/study regimen if it does not resolve', 'symptoms of a potential decompensation as described', 'to Grade 1 within 30 days or if there', 'above.', 'are signs of respiratory insufficiency or', 'Obtain a neurology consult', 'autonomic instability.', 'Sensory neuropathy/neuropathic pain may be managed by', 'appropriate medications (e.g., gabapentin or duloxetine).', 'MYASTHENIA GRAVIS:', 'Steroids may be successfully used to treat myasthenia', 'gravis. It is important to consider that steroid therapy', '(especially with high doses) may result in transient', 'worsening of myasthenia and should typically be', 'administered in a monitored setting under supervision of a', 'neurologist.', 'Patients unable to tolerate steroids may be candidates for', 'treatment with plasmapheresis or IV immunoglobulin', '(IG). Such decisions are best made in consultation with a', 'neurologist, taking into account the unique needs of each', 'patient.', 'If myasthenia gravis-like neurotoxicity is present,', 'consider starting acetylcholinesterase (AChE) inhibitor', 'therapy in addition to steroids. Such therapy, if successful,', 'can also serve to reinforce the diagnosis.', 'GUILLAIN-BARRE:', 'It is important to consider here that the use of steroids as', 'the primary treatment of Guillain-Barre is not typically', 'considered effective.', 'Patients requiring treatment should be started with IV IG', 'and followed by plasmapheresis if not responsive to IV', 'IG.', 'Grade 3 or 4 (Severe', 'For Grade 3:', 'For Grade 3 or 4 (severe or life-threatening events):', 'symptoms; limiting self', 'care ADL or life-', 'Hold study drug/study regimen dose', 'Consider, as necessary, discussing with study physician.', 'until resolution to Grade 1.', 'threatening', 'Recommend hospitalization.', 'consequences)', 'Permanently discontinue study', 'Monitor symptoms and obtain neurological consult.', 'drug/study regimen if Grade 3 imAE', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 33 de 123']\n\n###\n\n", "completion": "END"}